School of Medicine
Showing 1-10 of 11 Results
-
Donald Regula, MD
Professor (Teaching) of Pathology and, by courtesy, of Orthopaedic Surgery
Bio Dr. Regula is a course director for the required medical student course, Science of Medicine.
-
Kerri E. Rieger, MD, PhD
Clinical Associate Professor, Pathology
Bio Dr. Rieger is a Clinical Associate Professor of Pathology and Dermatology at Stanford University. She received her M.D., Ph.D. from Stanford University School of Medicine and completed her Dermatology Residency and Dermatopathology Fellowship at Stanford University. She is board certified in Dermatology and Dermatopathology. She evaluates skin specimens in the Pathology department, where her interests include histopathologic findings in hospitalized patients and patients with autoimmune disease. She also sees patients in the dermatology clinic at the Stanford Medicine Outpatient Center in Redwood City, where her clinical interest is adult general dermatology.
-
Suman Rimal
Postdoctoral Research Fellow, Pathology
Bio Research interests: Genetic mechanism underlying mitochondrial pathology, neurodegeneration, and muscle loss using Drosophila as a model organism.
-
Tyler Risom
Postdoctoral Research Fellow, Pathology
Bio My work utilizes multiplexed ion beam imaging (MIBI) to understand how tumor cells, immune cells, and stromal cells interact in pre-invasive breast, lung, and prostate tumors, and specifically, which 'bad actors' may drive progression to invasive carcinoma. MIBI has the unparalleled ability to simultaneously measure 50+ markers in a single tumor region, allowing us to measure the many cell types that exist within tumors, how these cell types are spatially related, and how they change in frequency, identity, and signalling as tumors progress to invasive carcinoma. A better understanding of the cellular changes that support transition to invasive cancer will allow us to design clinical tests to identify which patients are at risk of progression, and which are not, allowing oncologists to spare tens of thousands patients per year with low-risk tumors the unnecessary surgery, chemotherapy, and radiation that may be of no benefit. Further, through these investigations I seek to identify new molecular targets that can prevent or halt tumor progression, allowing us to design therapeutics that can combat cancer at this early, sensitive state.
